AbbVie (ABBV) Other Working Capital Changes (2012 - 2026)

AbbVie has disclosed Other Working Capital Changes across 15 years of filings, most recently posting $150.0 million for Q1 2026.

• In Q1 2026, Other Working Capital Changes fell 76.11% year-over-year to $150.0 million; the TTM figure through Mar 2026 stood at $349.0 million (down 36.66% YoY), while the FY2025 annual figure was $827.0 million, up 329.09% from the prior year.
• Other Working Capital Changes retreated to $150.0 million in Q1 2026, from $658.0 million in the prior quarter.
• Over the last five years, Other Working Capital Changes for ABBV reached as high as $658.0 million in Q4 2025 and fell as low as -$452.0 million in Q2 2023.
• The 5-year median for Other Working Capital Changes is $74.0 million (2022), against an average of $62.8 million.
• The widest YoY moves for Other Working Capital Changes: up 558.0% in 2025, down 1384.0% in 2025.
• A 5-year view of Other Working Capital Changes shows it stood at $204.0 million in 2022, then jumped by 185.29% to $582.0 million in 2023, then plunged by 82.82% to $100.0 million in 2024, then surged by 558.0% to $658.0 million in 2025, then tumbled by 77.2% to $150.0 million in 2026.
• According to Business Quant data, Other Working Capital Changes over the past three periods registered $150.0 million, $658.0 million, and -$88.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.